Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Dat Ngo, Jose Tinajero, Karamjeet Sandhu, Idoroenyi Amanam, Salman Otoukesh, Shukaib Arslan, Sunmin Park, Haris Ali, Badri Modi, Ryotaro Nakamura, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 7612.

https://doi.org/10.1182/blood-2025-7612

Published: 2025

Journal Articles

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Klara Kim, Dat Ngo, Jose Tinajero, Dongyun Yang, Haoyue Shan, Karamjeet Sandhu, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Shukaib Arslan, Vaibhav Agrawal, Sunmin Park, Ryotaro Nakamura, Monzr M. Al Malki, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 935.

https://doi.org/10.1182/blood-2025-935

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US

Idoroenyi Amanam, Chidera Agu, Siddhi Korgaonkar, Abigail Hitchens, I-Hsuan Su, Svetlana Gavrilov, Derek Tang, Rohan C. Parikh, Keith Davis, Samantha Slaff

Blood (2025) 146 (Supplement 1): 4620.

https://doi.org/10.1182/blood-2025-4620

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Blood (2025) 146 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2025-2516

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Blood (2025) 146 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2025-4282

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh, Yile Zhou, Bin Zhang, Dauh-Lian Chi, Tim Synold, John Williams, Monzr M. Al Malki, Haris Ali, Guido Marcucci

Blood (2025) 146 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2025-5593

Published: 2025

Journal Articles

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Idoroenyi Amanam, Lucy Ghoda, Monzr M. Al Malki, Karamjeet Sandhu, Andrew Artz, Amanda Blackmon, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Salman Otoukesh, Haris Ali

Blood (2025) 146 (Supplement 1): 5592.

https://doi.org/10.1182/blood-2025-5592

Published: 2025

Journal Articles

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh, Andrew Artz, Amanda Blackmon, Karamjeet Sandhu, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Monzr M. Al Malki, Haris Ali

Blood (2025) 146 (Supplement 1): 5591.

https://doi.org/10.1182/blood-2025-5591

Published: 2025

Journal Articles

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood (2025) 146 (Supplement 1): 508.

https://doi.org/10.1182/blood-2025-508

Published: 2025

Journal Articles

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

Kaito Harada, Dandan Zhao, Miso Park, Fang Chen, Yongfang Xu, Yi Zhang, Yile Zhou, Bea Parcutela, Yead Jewel, Ashlie Munoz, Idoroenyi Amanam, Le Xuan Truong Nguyen, Jianjun Chen, Lucy Ghoda, Stephen Forman, John Williams, Bin Zhang, Guido Marcucci

Blood (2025) 146 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2025-2340

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Blood (2024) 144 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2024-207125

Published: 2024

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Blood (2024) 144 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2024-200999

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Risk prediction for clonal cytopenia: multicenter real-world evidence

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only